Demonstrator Projects

One of the goals of the REMEDi4ALL projects is to develop an innovation platform supporting promising, high-impact drug repurposing projects championed by patients in any phase of development and disease area. To test the platform’s viability and robustness, we support four real-world projects on infectious diseases, rare cancers, and rare/ultra rare diseases.

• • COVID-19
    Validation of drugs and combinations for novel host targets in SARS-Cov-2 infection.
  • MULTIPLE SULFATASE DEFICIENCY
    Clinical PhI/II open label repurposing trial with tazarotene to assess safety/efficacy for treatment of MSD patients.
  • OSTEOGENESIS IMPERFECTA
    Repurposing of losartan for treatment of Osteogenesis imperfecta patients (OI).
  • PANCREATIC CANCER
    Repurposing of valproic acid combined with simvastatin to potentiate first line gemcitabine/nab-paclitaxel chemotherapy regimen in metastatic pancreatic cancer (mPDAC) patients.